Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Arber Shehu"'
Autor:
Caitlin Turbyfill, Katherine Adams, Mark W. Tenforde, Nancy L. Murray, Manjusha Gaglani, Adit A. Ginde, Tresa McNeal, Shekhar Ghamande, David J. Douin, H. Keipp Talbot, Jonathan D. Casey, Nicholas M. Mohr, Anne Zepeski, Nathan I. Shapiro, Kevin W. Gibbs, D. Clark Files, David N. Hager, Arber Shehu, Matthew E. Prekker, Anne E. Frosch, Matthew C. Exline, Michelle N. Gong, Amira Mohamed, Nicholas J. Johnson, Vasisht Srinivasan, Jay S. Steingrub, Ithan D. Peltan, Samuel M. Brown, Emily T. Martin, Adam S. Lauring, Akram Khan, Laurence W. Busse, Caitlin C. ten Lohuis, Abhijit Duggal, Jennifer G. Wilson, Alexandra June Gordon, Nida Qadir, Steven Y. Chang, Christopher Mallow, Carolina Rivas, Jennie H. Kwon, Natasha Halasa, James D. Chappell, Carlos G. Grijalva, Todd W. Rice, William B. Stubblefield, Adrienne Baughman, Jillian P. Rhoads, Christopher J. Lindsell, Kimberly W. Hart, Meredith McMorrow, Diya Surie, Wesley H. Self, Manish M. Patel
Publikováno v:
Vaccine, vol 40, iss 48
BackgroundTest-negative design (TND) studies have produced validated estimates of vaccine effectiveness (VE) for influenza vaccine studies. However, syndrome-negative controls have been proposed for differentiating bias and true estimates in VE evalu
Autor:
Diya, Surie, Levi, Bonnell, Katherine, Adams, Manjusha, Gaglani, Adit A, Ginde, David J, Douin, H Keipp, Talbot, Jonathan D, Casey, Nicholas M, Mohr, Anne, Zepeski, Tresa, McNeal, Shekhar, Ghamande, Kevin W, Gibbs, D Clark, Files, David N, Hager, Arber, Shehu, Anne P, Frosch, Heidi L, Erickson, Michelle N, Gong, Amira, Mohamed, Nicholas J, Johnson, Vasisht, Srinivasan, Jay S, Steingrub, Ithan D, Peltan, Samuel M, Brown, Emily T, Martin, Akram, Khan, William S, Bender, Abhijit, Duggal, Jennifer G, Wilson, Nida, Qadir, Steven Y, Chang, Christopher, Mallow, Carolina, Rivas, Jennie H, Kwon, Matthew C, Exline, Adam S, Lauring, Nathan I, Shapiro, Natasha, Halasa, James D, Chappell, Carlos G, Grijalva, Todd W, Rice, William B, Stubblefield, Adrienne, Baughman, Kelsey N, Womack, Kimberly W, Hart, Sydney A, Swan, Yuwei, Zhu, Jennifer, DeCuir, Mark W, Tenforde, Manish M, Patel, Meredith L, McMorrow, Wesley H, Self, Carleigh, Samuels
Publikováno v:
MMWR. Morbidity and Mortality Weekly Report. 71:1327-1334
The SARS-CoV-2 Omicron variant (B.1.1.529 or BA.1) became predominant in the United States by late December 2021 (1). BA.1 has since been replaced by emerging lineages BA.2 (including BA.2.12.1) in March 2022, followed by BA.4 and BA.5, which have ac
Autor:
Nathaniel M, Lewis, Wesley H, Self, Manjusha, Gaglani, Adit A, Ginde, David J, Douin, H, Keipp Talbot, Jonathan D, Casey, Nicholas M, Mohr, Anne, Zepeski, Shekhar A, Ghamande, Tresa A, McNeal, Nathan I, Shapiro, Kevin W, Gibbs, D Clark, Files, David N, Hager, Arber, Shehu, Matthew E, Prekker, Heidi L, Erickson, Michelle N, Gong, Amira, Mohamed, Nicholas J, Johnson, Vasisht, Srinivasan, Jay S, Steingrub, Ithan D, Peltan, Samuel M, Brown, Emily T, Martin, Arnold S, Monto, Akram, Khan, Laurence W, Busse, Caitlin C Ten, Lohuis, Abhijit, Duggal, Jennifer G, Wilson, Alexandra June, Gordon, Nida, Qadir, Steven Y, Chang, Christopher, Mallow, Carolina, Rivas, Hilary M, Babcock, Jennie H, Kwon, Matthew C, Exline, Adam S, Lauring, Natasha, Halasa, James D, Chappell, Carlos G, Grijalva, Todd W, Rice, Jillian P, Rhoads, Ian D, Jones, William B, Stubblefield, Adrienne, Baughman, Kelsey N, Womack, Christopher J, Lindsell, Kimberly W, Hart, Yuwei, Zhu, Katherine, Adams, Manish M, Patel, Mark W, Tenforde
Publikováno v:
Clinical Infectious Diseases. 75:S159-S166
Background . Adults in the United States (US) began receiving the adenovirus vector coronavirus disease 2019 (COVID-19) vaccine, Ad26.COV2.S (Johnson & Johnson [Janssen]), in February 2021. We evaluated Ad26.COV2.S vaccine effectiveness (VE) against
Autor:
Anne Zepeski, Catherine L. Hough, Wesley H. Self, Ian Jones, Amira Mohamed, Tresa McNeal, Samuel M. Brown, Shekhar Ghamande, Jennifer G. Wilson, Alexandra June Gordon, Eric A. Naioti, Manjusha Gaglani, Jay S. Steingrub, Steven Y. Chang, Natalie J. Thornburg, Yuwei Zhu, Adrienne Baughman, Mark W Tenforde, Matthew E. Prekker, Christopher J. Lindsell, William B. Stubblefield, Arnold S. Monto, Nida Qadir, James D. Chappell, Nicholas M. Mohr, Carolina Rivas, Sandra N. Lester, Abhijit Duggal, Ithan D. Peltan, Kevin W Gibbs, Jillian P. Rhoads, Jennifer R. Verani, Miwako Kobayashi, Hilary M. Babcock, Manish M. Patel, Arber Shehu, Emily T. Martin, Natasha B. Halasa, Laurence W. Busse, Megan M. Stump, Jennie H. Kwon, David J. Douin, Daniel J. Henning, Matthew C. Exline, Kelsey N Womack, Michelle N. Gong, Todd W. Rice, Samantha M. Olson, H. Keipp Talbot, Adam S. Lauring, Jonathan D Casey, Adit A. Ginde, Kimberly W. Hart, Heidi L Erickson, D. Clark Files, David N. Hager, Carlos G. Grijalva, Lisa Mills, Christopher Mallow, Akram Khan, Caitlin C Ten Lohuis
Publikováno v:
Morbidity and Mortality Weekly Report
Three COVID-19 vaccines are authorized or approved for use among adults in the United States (1,2). Two 2-dose mRNA vaccines, mRNA-1273 from Moderna and BNT162b2 from Pfizer-BioNTech, received Emergency Use Authorization (EUA) by the Food and Drug Ad
Autor:
Mark W, Tenforde, Wesley H, Self, Yuwei, Zhu, Eric A, Naioti, Manjusha, Gaglani, Adit A, Ginde, Kelly, Jensen, H Keipp, Talbot, Jonathan D, Casey, Nicholas M, Mohr, Anne, Zepeski, Tresa, McNeal, Shekhar, Ghamande, Kevin W, Gibbs, D Clark, Files, David N, Hager, Arber, Shehu, Matthew E, Prekker, Heidi L, Erickson, Michelle N, Gong, Amira, Mohamed, Nicholas J, Johnson, Vasisht, Srinivasan, Jay S, Steingrub, Ithan D, Peltan, Samuel M, Brown, Emily T, Martin, Arnold S, Monto, Akram, Khan, Catherine L, Hough, Laurence W, Busse, Caitlin, Ten Lohuis, Abhijit, Duggal, Jennifer G, Wilson, Nida, Qadir, Steven Y, Chang, Christopher, Mallow, Carolina, Rivas, Hilary M, Babcock, Jennie H, Kwon, Matthew C, Exline, Mena M, Botros, Adam S, Lauring, Nathan I, Shapiro, Natasha, Halasa, James D, Chappell, Carlos G, Grijalva, Todd W, Rice, Ian D, Jones, William B, Stubblefield, Adrienne, Baughman, Kelsey N, Womack, Jillian P, Rhoads, Christopher J, Lindsell, Kimberly W, Hart, Caitlin, Turbyfill, Samantha, Olson, Nancy, Murray, Katherine, Adams, Manish M, Patel
Publikováno v:
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
COVID-19 mRNA vaccines were authorized in the United States in December 2020. Although vaccine effectiveness (VE) against mild infection declines markedly after several months, limited understanding exists on the long-term durability of protection ag
Autor:
Jennie H Kwon, Mark W Tenforde, Manjusha Gaglani, H Keipp Talbot, Adit A Ginde, Tresa McNeal, Shekhar Ghamande, David J Douin, Jonathan D Casey, Nicholas M Mohr, Anne Zepeski, Nathan I Shapiro, Kevin W Gibbs, D Clark Files, David N Hager, Arber Shehu, Matthew E Prekker, Sean D Caspers, Matthew C Exline, Mena Botros, Michelle N Gong, Alex Li, Amira Mohamed, Nicholas J Johnson, Vasisht Srinivasan, Jay S Steingrub, Ithan D Peltan, Samuel M Brown, Emily T Martin, Akram Khan, Catherine L Hough, Laurence W Busse, Abhijit Duggal, Jennifer G Wilson, Cynthia Perez, Steven Y Chang, Christopher Mallow, Randal Rovinski, Hilary M Babcock, Adam S Lauring, Laura Felley, Natasha Halasa, James D Chappell, Carlos G Grijalva, Todd W Rice, Kelsey N Womack, Christopher J Lindsell, Kimberly W Hart, Adrienne Baughman, Samantha M Olson, Stephanie Schrag, Miwako Kobayashi, Jennifer R Verani, Manish M Patel, Wesley H Self
Publikováno v:
The Journal of infectious diseases. 226(5)
Background The study objective was to evaluate 2- and 3-dose coronavirus disease 2019 (COVID-19) mRNA vaccine effectiveness (VE) in preventing COVID-19 hospitalization among adult solid organ transplant (SOT) recipients. Methods We conducted a 21-sit
Autor:
Amira Mohamed, Catherine L. Hough, Manjusha Gaglani, Nathan I. Shapiro, Samantha M. Olson, Abhijit Duggal, Arber Shehu, Manish M. Patel, Kimberly W. Hart, Laurence W. Busse, William B Stubblefield, Emily T. Martin, Ithan D. Peltan, Caitlin C Ten Lohuis, Kevin W Gibbs, Jillian P. Rhoads, Mark W Tenforde, Tresa McNeal, Miwako Kobayashi, Jennifer G. Wilson, Christopher J. Lindsell, Alexandra June Gordon, Kelsey N Womack, Steven Y. Chang, Jay S. Steingrub, Samuel M. Brown, Anne Zepeski, Carolina Rivas, Daniel J. Henning, Jennie H. Kwon, Christopher Mallow, Michelle N. Gong, Shekhar Ghamande, Todd W. Rice, Adrienne Baughman, Influenza, Jennifer R. Verani, Arnold S. Monto, Nida Qadir, James D. Chappell, Akram Khan, Nicholas M. Mohr, Natasha B. Halasa, H. Keipp Talbot, Hilary M. Babcock, David J. Douin, Yuwei Zhu, Carlos G. Grijalva, Matthew E. Prekker, Wesley H. Self, D. Clark Files, David N. Hager, Katherine Adams, Adam S. Lauring, Ian Jones, Matthew C. Exline, Heidi L Erickson, Jonathan D Casey, Adit A. Ginde
Publikováno v:
JAMA
IMPORTANCE: A comprehensive understanding of the benefits of COVID-19 vaccination requires consideration of disease attenuation, determined as whether people who develop COVID-19 despite vaccination have lower disease severity than unvaccinated peopl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d0de4b15d4eaf88d751fd07e65278925
https://europepmc.org/articles/PMC8569602/
https://europepmc.org/articles/PMC8569602/
Autor:
Wesley H. Self, Jennifer R. Verani, Caitlin C Ten Lohuis, Abhijit Duggal, Hayley B. Gershengorn, Matthew E. Prekker, Natasha B. Halasa, Laurence W. Busse, Christopher J. Lindsell, Samuel M. Brown, Ian Jones, Christopher Mallow, Emily T. Martin, Adrienne Baughman, Akram Khan, Amira Mohamed, Kevin W Gibbs, Ithan D. Peltan, Tresa McNeal, Carlos G. Grijalva, Miwako Kobayashi, Arber Shehu, Shekhar Ghamande, Adam S. Lauring, Matthew C. Exline, Jonathan D Casey, William B Stubblefield, Jennifer G. Wilson, Alexandra June Gordon, Jennie H. Kwon, Michelle N. Gong, Todd W. Rice, Kelsey N Womack, Steven Y. Chang, Adit A. Ginde, Daniel J. Henning, Heidi L Erickson, Nathan I. Shapiro, D. Clark Files, David N. Hager, Samantha M. Olson, Stephanie J. Schrag, H. Keipp Talbot, Anne Zepeski, Mark W Tenforde, David J. Douin, Influenza, Yuwei Zhu, Nicholas M. Mohr, Manish M. Patel, Kimberly W. Hart, Jay S. Steingrub, Meagan Stephenson, Manjusha Gaglani, C Terri Hough, Arnold S. Monto, Nida Qadir, James D. Chappell, Hilary M. Babcock
Publikováno v:
Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
BackgroundAs SARS-CoV-2 vaccination coverage increases in the United States (US), there is a need to understand the real-world effectiveness against severe Covid-19 and among people at increased risk for poor outcomes.MethodsIn a multicenter case-con
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::114ab165f1aa423e0425fea0cccb4118
https://doi.org/10.1101/2021.07.08.21259776
https://doi.org/10.1101/2021.07.08.21259776
Autor:
Mark W, Tenforde, Manish M, Patel, Adit A, Ginde, David J, Douin, H Keipp, Talbot, Jonathan D, Casey, Nicholas M, Mohr, Anne, Zepeski, Manjusha, Gaglani, Tresa, McNeal, Shekhar, Ghamande, Nathan I, Shapiro, Kevin W, Gibbs, D Clark, Files, David N, Hager, Arber, Shehu, Matthew E, Prekker, Heidi L, Erickson, Matthew C, Exline, Michelle N, Gong, Amira, Mohamed, Daniel J, Henning, Jay S, Steingrub, Ithan D, Peltan, Samuel M, Brown, Emily T, Martin, Arnold S, Monto, Akram, Khan, Catherine L, Hough, Laurence W, Busse, Caitlin C, Ten Lohuis, Abhijit, Duggal, Jennifer G, Wilson, Alexandra June, Gordon, Nida, Qadir, Steven Y, Chang, Christopher, Mallow, Hayley B, Gershengorn, Hilary M, Babcock, Jennie H, Kwon, Natasha, Halasa, James D, Chappell, Adam S, Lauring, Carlos G, Grijalva, Todd W, Rice, Ian D, Jones, William B, Stubblefield, Adrienne, Baughman, Kelsey N, Womack, Christopher J, Lindsell, Kimberly W, Hart, Yuwei, Zhu, Samantha M, Olson, Meagan, Stephenson, Stephanie J, Schrag, Miwako, Kobayashi, Jennifer R, Verani, Wesley H, Self
Publikováno v:
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 74(9)
Background As severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination coverage increases in the United States, there is a need to understand the real-world effectiveness against severe coronavirus disease 2019 (COVID-19) and among pe
Autor:
Mark W, Tenforde, Samantha M, Olson, Wesley H, Self, H Keipp, Talbot, Christopher J, Lindsell, Jay S, Steingrub, Nathan I, Shapiro, Adit A, Ginde, David J, Douin, Matthew E, Prekker, Samuel M, Brown, Ithan D, Peltan, Michelle N, Gong, Amira, Mohamed, Akram, Khan, Matthew C, Exline, D Clark, Files, Kevin W, Gibbs, William B, Stubblefield, Jonathan D, Casey, Todd W, Rice, Carlos G, Grijalva, David N, Hager, Arber, Shehu, Nida, Qadir, Steven Y, Chang, Jennifer G, Wilson, Manjusha, Gaglani, Kempapura, Murthy, Nicole, Calhoun, Arnold S, Monto, Emily T, Martin, Anurag, Malani, Richard K, Zimmerman, Fernanda P, Silveira, Donald B, Middleton, Yuwei, Zhu, Dayna, Wyatt, Meagan, Stephenson, Adrienne, Baughman, Kelsey N, Womack, Kimberly W, Hart, Miwako, Kobayashi, Jennifer R, Verani, Manish M, Patel, Tnelda, Zunie
Publikováno v:
MMWR. Morbidity and mortality weekly report. 70(18)
Adults aged ≥65 years are at increased risk for severe outcomes from COVID-19 and were identified as a priority group to receive the first COVID-19 vaccines approved for use under an Emergency Use Authorization (EUA) in the United States (1-3). In